ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1781

Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature

Martha Decker1, Christian Pagnoux2, Constance Chik3, Nader A. Khalidi4, Derek Emery5 and Elaine Yacyshyn6, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 3Division of Endocrinology, University of Alberta, Edmonton, AB, Canada, 4Rheumatology, McMaster University, Hamilton, ON, Canada, 5Division of Radiology, University of Alberta, Edmonton, AB, Canada, 6Medicine, University of Alberta, Edmonton, AB, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Wegener's granulomatosis and central nervous system involvement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Vasculitis Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pituitary involvement in granulomatosis with polyangiitis (GPA) is rare with an incidence of approximately 1%. Objectives were: (1) Describe ten new cases of pituitary involvement in GPA seen at Canadian healthcare institutions; (2) Perform a literature review of pituitary involvement in GPA and compare previously reported cases with our series.

Methods: We surveyed members of the Canadian Vasculitis Research Network (CanVasc; 18 centers across Canada) for patients with GPA and pituitary disease. Cases were defined based on: (1) Clinical characteristics consistent with GPA; (2) Pituitary MRI/pituitary histology consistent with GPA, with or without hormonal dysfunction; (3) Exclusion of alternative causes of pituitary disease. Clinical details were collected using a standardized record form. We performed a literature search of the following databases: Medline, Embase, Scopus, and Proquest, using “granulomatosis with polyangiitis” and “pituitary” as keywords.

Results:

Our case series included 10 patients (9 female, 1 male). Mean age at GPA diagnosis and presentation of pituitary disease were: 33.8 years (range 13 to 56) and 35.3 years (range 18 to 56), respectively. Five patients presented with pituitary disease at GPA diagnosis; mean time from GPA to pituitary disease diagnosis was 3.4 years for the remaining five. Nine patients were ANCA positive (PR3 for 8, MPO for 1). Diabetes insipidus (DI) was the most frequent hormonal dysfunction observed (n = 8). Hypogonadism and central hypothyroidism were seen in 3 and 2 patients, respectively. Pituitary hormone testing was normal in 2 patients (presenting with pituitary mass only). All patients had GPA involvement at other sites including ENT (n = 8), pulmonary (n = 6), and renal (n = 4). Eight patients received therapy including glucocorticoids alone (n = 1), with IV cyclophosphamide (CYC, n = 2), oral CYC (n = 3) or rituximab (n = 1), or a combination of mycophenolate mofetil and tacrolimus (n = 1). All patients had systemic disease remission on follow-up. Hormonal deficiencies were persistent after treatment in all patients with pituitary dysfunction at baseline. Our literature review yielded 67 other cases of pituitary involvement in GPA. The largest series included 9 patients. A limitation of our series, and previous case reports, is the lack of pituitary histology to definitively exclude an alternative cause for pituitary disease arising concurrently with GPA. Tissue is rarely obtained unless there is a surgical indication (e.g. compression of the optic chiasm) or a diagnostic dilemma exists, such as in isolated pituitary GPA.

Conclusion: This new and large case series of pituitary disease and GPA, together with previously reported cases, suggest: (1) Pituitary disease may be diagnosed concurrent to systemic GPA or later; (2) Pituitary disease is rarely isolated; (3) Posterior pituitary dysfunction is the most common disease manifestation; (4) Pituitary disease does not seem to negatively impact the global prognosis; (5) Pituitary dysfunction and need for hormone supplementation are often irreversible.


Disclosure: M. Decker, None; C. Pagnoux, None; C. Chik, None; N. A. Khalidi, None; D. Emery, None; E. Yacyshyn, None.

To cite this abstract in AMA style:

Decker M, Pagnoux C, Chik C, Khalidi NA, Emery D, Yacyshyn E. Pituitary Disease and Granulomatosis with Polyangiitis: A Collaborative Canadian Case Series and Review of the Literature [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pituitary-disease-and-granulomatosis-with-polyangiitis-a-collaborative-canadian-case-series-and-review-of-the-literature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pituitary-disease-and-granulomatosis-with-polyangiitis-a-collaborative-canadian-case-series-and-review-of-the-literature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology